Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin

Molecular Cancer

Volumn 7, Issue , 2008, Pages

  Burkitt, Kyunghee ^a,b   Ljungman, Mats ^a,b  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; CISPLATIN; FANCONI ANEMIA GROUP D2 PROTEIN; FANCONI ANEMIA PROTEIN; PHENYLBUTYRATE; UNCLASSIFIED DRUG; 4 PHENYLBUTYRIC ACID; 4-PHENYLBUTYRIC ACID; ARYLBUTYRIC ACID DERIVATIVE; BRCA1 PROTEIN, HUMAN; FANCD2 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CHEMOSENSITIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; UBIQUITINATION; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; HEAD AND NECK TUMOR; METABOLISM; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; CISPLATIN; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; HEAD AND NECK NEOPLASMS; HUMANS; PHENYLBUTYRATES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 41549164782     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-7-24     Document Type: Article

References (32)

1. Boulikas T Vougiouka M Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs Oncol Rep 2004, 11:559-595
2. Kelland L The resurgence of platinum-based cancer chemotherapy Nat Rev Cancer 2007, 7:573-584 10.1038/nrc2167
3. Taniguchi T Tischkowitz M Ameziane N Hodgson SV Mathew CG Joenje H Mok SC D'Andrea AD Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors Nat Med 2003, 9:568-574 10.1038/nm852
4. D'Andrea AD Grompe M The Fanconi anaemia BRCA pathway Nat Rev Cancer 2003, 3:23-34 10.1038/nrc970
5. Mirchandani KD D'Andrea AD The Fanconi anemia/BRCA pathway: A coordinator of cross-link repair Exp Cell Res 2006, 312:2647-2653 10.1016/j.yexcr.2006.06.014
6. Burkitt K Ljungman M Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines Cancer Lett 2007, 253:131-137 10.1016/j.canlet.2007.01.017
7. Friedberg E Walker G Siede W Wood R Schultz R Ellenberger T DNA Repair and Mutagenesis Washington, D.C.: ASM Press Second 2006
8. Siddik ZH Cisplatin: Mode of cytotoxic action and molecular basis of resistance Oncogene 2003, 22:7265-7279 10.1038/sj.onc.1206933
9. Wang D Lippard SJ Cellular processing of platinum anticancer drugs Nat Rev Drug Discov 2005, 4:307-320 10.1038/nrd1691
10. McHugh PJ Sarkar S DNA Interstrand Cross-Link Repair in the Cell Cycle: A Critical Role for Polymerase zeta in G(1) Phase Cell Cycle 2006, 5:1044-1047
11. Albertella MR Green CM Lehmann AR O'Connor MJ A role for polymerase eta in the cellular tolerance to cisplatin-induced damage Cancer Res 2005, 65:9799-9806 10.1158/0008-5472.CAN-05-1095
12. Chirnomas D Taniguchi T de la Vega M Vaidya AP Vasserman M Hartman AR Kennedy R Foster R Mahoney J Seiden MV D'Andrea AD Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway Mol Cancer Ther 2006, 5:952-961 10.1158/1535-7163.MCT-05-0493
13. Moynahan ME Cui TY Jasin M Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation Cancer Res 2001, 61:4842-4850
14. Chung DH Zhang FF Chen F McLaughlin WP Ljungman M Butyrate attenuates BCLXL expression in human fibroblasts and acts in synergy with ionizing radiation to induce apoptosis Radiat Res 1998, 149:187-194 10.2307/ 3579929
15. Witzig TE Timm M Stenson M Svingen PA Kaufmann SH Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents Clin Cancer Res 2000, 6:681-692
16. Goh M Chen F Paulsen MT Yeager AM Dyer ES Ljungman M Phenylbutyrate attenuates the expression of Bcl-X-L, DNA-PK, caveolin-1, and VEGF in prostate cancer cells Neoplasia 2001, 3:331-338 10.1038/sj.neo.7900165
17. Batshaw ML MacArthur RB Tuchman M Alternative pathway therapy for urea cycle disorders: Twenty years later J Pediatr 2001, 138:S46-54 discussion S54-45. 10.1067/mpd.2001.111836
18. Resar LMS Segal JB Fitzpatric LK Friedmann A Brusilow SW Dover GJ Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy J Pediat Hem Onc 2002, 24:737-741 10.1097/00043426-200212000-00011
19. Rubenstein RC Zeitlin PL A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in Delta F508-homozygous cystic fibrosis patients: Partial restoration of nasal epithelial CFTR function Amer J Respir Crit Care Med 1998, 157:484-490
20. Monneret C Histone deacetylase inhibitors Eur J Med Chem 2005, 40:1-13 10.1016/j.ejmech.2004.10.001
21. Dyer ES Paulsen MT Markwart SM Goh M Livant DL Ljungman M Phenylbutyrate inhibits the invasive properties of prostate and breast cancer cell lines in the sea urchin embryo basement membrane invasion assay Int J Cancer 2002, 101:496-499 10.1002/ijc.10609
22. Garcia-Higuera I Taniguchi T Ganesan S Meyn MS Timmers C Hejna J Grompe M D'Andrea AD Interaction of the fanconi anemia proteins and BRCA1 in a common pathway Mol Cell 2001, 7:249-262 10.1016/S1097-2765(01)00173-3
23. Vandenberg CJ Gergely F Ong CY Pace P Mallery DL Hiom K Patel KJ BRCA1-independent ubiquitination of FANCD2 Mol Cell 2003, 12:247-254 10.1016/S1097-2765(03)00281-8
24. Bradford CR Zhu S Ogawa H Ogawa T Ubell M Narayan A Johnson G Wolf GT Fisher SG Carey TE P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines Head Neck 2003, 25:654-661 10.1002/hed.10274
25. Petrie K Prodromou N Zelent A Histone deacetylase inhibitors in APL and beyond Curr Top Microbiol Immunol 2007, 313:157-203
26. Bolden JE Peart MJ Johnstone RW Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 2006, 5:769-784 10.1038/ nrd2133
27. Huang TT D'Andrea AD Regulation of DNA repair by ubiquitylation Nat Rev Mol Cell Biol 2006, 7:323-334 10.1038/nrm1908
28. Tassone P Tagliaferri P Perricelli A Blotta S Quaresima B Martelli ML Goel A Barbieri V Costanzo F Boland CR Venuta S BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells Br J Cancer 2003, 88:1285-1291 10.1038/sj.bjc.6600859
29. Quinn JE James CR Stewart GE Mulligan JM White P Chang GK Mullan PB Johnston PG Wilson RH Harkin DP BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy Clin Cancer Res 2007, 13:7413-7420 10.1158/1078-0432.CCR-07-1083
30. Quinn JE Kennedy RD Mullan PB Gilmore PM Carty M Johnston PG Harkin DP BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis Cancer Res 2003, 63:6221-6228
31. Sylvain V Lafarge S Bignon YJ Dominant-negative activity of a Brca1 truncation mutant: Effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line Int J Oncol 2002, 20:845-853
32. Ljungman M Zhang F Blockage of RNA polymerase as a possible trigger for uv light-induced apoptosis Oncogene 1996, 13:823-831